HORMONE RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weapon tested against tough cancers in major global trial
Disease control OngoingThis is the first time a new drug called DS-1062a is being tested in people. The main goal is to find a safe and tolerable dose for patients with advanced solid tumors, including lung and breast cancers, that have not responded to standard treatments. The study will also test if …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat breast cancer: drug combo trial aims to shrink tumors before surgery
Disease control OngoingThis study is testing if adding a targeted drug called pyrotinib to standard chemotherapy before surgery works better than chemotherapy alone for people with a specific, high-risk type of early breast cancer. It will involve about 160 adults with hormone-positive, HER2-low breast…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat breast cancer? drug combo trial aims to shrink tumors before surgery
Disease control OngoingThis study is testing if adding an oral drug called pyrotinib to standard chemotherapy before surgery is more effective for a specific type of breast cancer. It involves 140 women with stage II-III, hormone-positive, HER2-negative breast cancer that has high levels of a protein c…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Early trial tests new combo for Tough-to-Treat breast cancer
Disease control OngoingThis early-stage study is testing the safety of combining two drugs—an oral chemotherapy called capecitabine and an immunotherapy drug called cemiplimab—for people with advanced hormone-positive breast cancer. The main goal is to find the safest and most effective dose for future…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC